Shanghai Longyao Biotechnology Inc., Ltd. Report issue

Government Phase 1 Phase 2

Organization Overview

First Clinical Trial
2017
NCT03207178
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Shanghai Longyao Bio-Tech Co., Ltd. | Shanghai Longyao Biotechnology Inc., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

cd19 car-t cells (2 trials)

cd20 car-t cells (3 trials)

Drugs in Phase 1 Trials (1)

ly011 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 3